
    
      Single administration, double-blinded, placebo-controlled (2 subjects in each group will take
      placebo,8 subjects in each group will take CY150112) and 6 dose groups (0.5mg, 1.5mg, 4.5mg,
      10mg, 18mg and 24mg).

      This study comprises a screening period (between signing of the informed consent form and Day
      -1), baseline period (Day -1), treatment period (Days 1-5) and follow-up period(Days 12 or 7
      days after discharge ).
    
  